GRAND RAPIDS, Mich.–(BUSINESS WIRE)–Carrie Kincaid, senior vice president of government markets and market development at Priority Health, a nationally recognized nonprofit health plan serving more than 1.4 million members, has been named as a Leading Women Honoree for 2026 by Modern Healthcare. The program honors influential women from all sectors of the health care industry, … [Read more…]
FRISCO, Texas–(BUSINESS WIRE)–Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced its participation at the following investor conferences: Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Monday, March 16, 2026. Dirk Allison, Chairman and Chief Executive Officer, and Brian Poff, Executive Vice President and Chief Financial Officer will participate in … [Read more…]
Part of the AI-Powered PracticeTM, ModMed Scribe is the fastest-growing product in ModMed history BOCA RATON, Fla.–(BUSINESS WIRE)–ModMed®, a leading provider of software and services to specialty medical practices, today announced that its new ModMed Scribe clinical AI Assistant has been used in more than 240,000 patient visits since launching version 2.0 in November 2025. … [Read more…]
Collaboration supports Controlled Human Infection Model (CHIM) studies that help accelerate development of effective and affordable RSV vaccines NANTES, France & GENEVA–(BUSINESS WIRE)–Naobios, a Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and GMP production of clinical batches of virus-based products, and SGS, the world’s leading testing, inspection and certification company, today announce their … [Read more…]
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment Genentech is committed to transforming ER-positive breast cancer care, anchored by … [Read more…]
Cetaphil’s new AM/PM Serums are powered by unique Gallic-AOX Power™ Technology, a patent-pending antioxidant complex clinically designed to sync to your skin’s circadian rhythm and support skin resilience Delivers advanced antioxidant protection by day1 and accelerated repair by night, with visible results in as little as 7 days2 In global testing, Gallic Acid demonstrated 2x … [Read more…]
Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials Sotyktu is the first and only tyrosine kinase 2 (TYK2) inhibitor to be approved for this indication PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #FDA—Bristol Myers Squibb (NYSE:BMY) today … [Read more…]
– Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe – The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin … [Read more…]
Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; MindWalk holds first right to commercialize jointly developed intellectual property AUSTIN, Texas–(BUSINESS WIRE)–$HYFT #ai–MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single-domain … [Read more…]
DALLAS & NEW YORK & LONDON & TOKYO–(BUSINESS WIRE)–Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position … [Read more…]
